A recent study by Gilcrease et al. has shown that any degree of HER2 overexpression (1+, 2+ or 3+) was associated with increased tumor recurrence and decreased patient survival in a node-positive cohort of breast cancer patients (n = 91) treated with doxorubicin-based chemotherapy without trastuzumab [36]. This evidence concerns the gene ERBB2 and neoplasm.